H2RA medication
Showing 1 - 25 of >10,000
End Stage Renal Disease, Hypertension, Diabete Type 2 Trial in Montreal (Medication reconciliation supplemented with MedSafer
Enrolling by invitation
- End Stage Renal Disease
- +5 more
- Medication reconciliation supplemented with MedSafer and deprescribing brochures
-
Montreal, Quebec, CanadaMcGill University Health Centre
Oct 15, 2022
Quantity of Opioids for Acute Pain and Limit Unused Medication
Recruiting
- Acute Pain
-
Kingston, Ontario, Canada
- +5 more
Nov 10, 2022
Depression Trial in Canada, United States (Clinical Decision Support System)
Recruiting
- Depression
- Clinical Decision Support System
-
Miami, Florida
- +12 more
Jul 14, 2022
H2 Receptor Antagonist and Proton Pump Inhibitor on Positivity
Not yet recruiting
- COVID-19
- No intervention (Retrospective Cohort Observational)
-
Seoul, Korea, Republic ofSeoul National University Hospital
Apr 6, 2021
Sedative Adverse Reaction, Anticholinergic Adverse Reaction Trial in Halifax (Intervention)
Active, not recruiting
- Sedative Adverse Reaction
- Anticholinergic Adverse Reaction
- Intervention
-
Halifax, Nova Scotia, CanadaNova Scotia Health Authority QE2/DGH
Mar 8, 2022
Drug Interaction Trial in Brisbane (Telaglenastat, Famotidine, Placebo for famotidine)
Completed
- Drug Interaction
- Telaglenastat
- +2 more
-
Brisbane, Queensland, AustraliaNucleus Network Brisbane Clinic (formerly Q-Pharm)
Mar 8, 2021
Selective CT for Anticoagulated Head Injured Patients
Recruiting
- Head Injury
- +3 more
-
Vancouver, British Columbia, Canada
- +6 more
May 5, 2022
Generalized Myasthenia Gravis Trial in Canada, United States (zilucoplan (RA101495), Placebo)
Completed
- Generalized Myasthenia Gravis
- zilucoplan (RA101495)
- Placebo
-
Mobile, Alabama
- +29 more
Jul 26, 2022
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Tumor in the Lymph Nodes, Metastatic Prostate Carcinoma Trial in
Recruiting
- Castration-Resistant Prostate Carcinoma
- +3 more
- Avelumab
- +4 more
-
Los Angeles, California
- +22 more
Feb 2, 2023
Chronic Spontaneous Urticaria, Recurrent Angioedema Trial in Germany (Dupilumab, Placebo)
Completed
- Chronic Spontaneous Urticaria
- Recurrent Angioedema
- Dupilumab
- Placebo
-
Marburg, Hessen, Germany
- +5 more
Feb 1, 2022
Metabolic Disturbance, Schizophrenia, Type 2 Diabetes Trial in Copenhagen (Semaglutide, 1.34 mg/mL, Semaglutide-)
Not yet recruiting
- Metabolic Disturbance
- +5 more
- Semaglutide, 1.34 mg/mL
- Semaglutide-placebo
-
Copenhagen, DenmarkPsychiatric Center Copenhagen, Rigshospitalet
Jun 30, 2021
Oral Upadacitinib Tablets to Assess Change in Disease Symptoms
Recruiting
- Rheumatoid Arthritis (RA)
-
Edmonton, Alberta, Canada
- +38 more
Jan 17, 2023
Malignant Solid Tumor Trial in Worldwide (BMS-986179, Nivolumab, rHuPH20)
Completed
- Malignant Solid Tumor
- BMS-986179
- +2 more
-
Chicago, Illinois
- +23 more
May 25, 2022
Hematopoietic and Lymphoid Cell Tumor, Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma Trial in Houston (Anakinra,
Active, not recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +8 more
- Anakinra
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 22, 2022
Kidney Tumors Trial in Halifax (Quill knotless tissue-closure device, 2-0 absorbable vicryl suture)
Terminated
- Kidney Neoplasms
- Quill knotless tissue-closure device
- 2-0 absorbable vicryl suture
-
Halifax, Nova Scotia, CanadaCDHA QEII site
Jul 27, 2021
Medication Errors and Other Product Use Errors and Issues Trial in San Juan De Alicante (360 videos, VR, AR)
Enrolling by invitation
- Medication Errors and Other Product Use Errors and Issues
- 360 videos
- +3 more
-
San Juan De Alicante, Alicante, SpainFundación Fisabio
May 22, 2023
Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes Trial in Worldwide (Inclisiran, Evolocumab)
Completed
- Atherosclerotic Cardiovascular Disease
- +3 more
-
Jacksonville, Florida
- +51 more
Feb 7, 2022
Mixed Dyslipidemia Trial in Worldwide (ARO-ANG3, Placebo)
Active, not recruiting
- Mixed Dyslipidemia
- ARO-ANG3
- Placebo
-
Huntington Park, California
- +23 more
Jun 27, 2022
Obesity, Liver Diseases, Liver Fibrosis Trial in Boston (ESG, GLP1-RA)
Not yet recruiting
- Obesity
- +16 more
- ESG
- GLP1-RA
-
Boston, MassachusettsBrigham and Women's Hospital
Nov 14, 2023
Diabetic Peripheral Neuropathic Pain Trial in Hangzhou (Basal therapy+EA, Basal therapy)
Not yet recruiting
- Diabetic Peripheral Neuropathic Pain
- Basal therapy+EA
- Basal therapy
-
Hangzhou, Zhejiang, Chinathe Third affiliated hospital of Zhejiang Chinese Medical univer
Sep 21, 2023
Fragile X Syndrome, Fragile X Mental Retardation Syndrome, Mental Retardation, X-Linked Trial in Edmonton, Montreal (Placebo
Recruiting
- Fragile X Syndrome
- +9 more
- Placebo Medication
- Metformin
-
Edmonton, Alberta, Canada
- +1 more
Sep 16, 2021
ADHD, Autism Spectrum Disorder Trial in Canada, United States (Randomization to either Amphetamine (AMP) class of stimulant
Not yet recruiting
- ADHD
- Autism Spectrum Disorder
- Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication
- Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
-
Irvine, California
- +11 more
Jun 14, 2023
Opioid Use, Spine Fusion Trial in Redwood City (Spinal Fusion Preoperative Opioid Taper, Non-taper Control)
Recruiting
- Opioid Use
- Spine Fusion
- Spinal Fusion Preoperative Opioid Taper
- Non-taper Control
-
Redwood City, CaliforniaStanford Hospital and Clinics
Jul 10, 2022